Literature DB >> 19828560

Lack of prophylaxis before the onset of acute venous thromboembolism among hospitalized cancer patients: the SWIss Venous ThromboEmbolism Registry (SWIVTER).

N Kucher1, D Spirk, I Baumgartner, L Mazzolai, W Korte, D Nobel, M Banyai, H Bounameaux.   

Abstract

BACKGROUND: Venous thromboembolism (VTE) prophylaxis remains underutilized, particularly in cancer patients. We explored clinical predictors of prophylaxis in hospitalized cancer patients before the onset of acute VTE.
METHODS: In the SWiss Venous ThromboEmbolism Registry, 257 cancer patients (61 +/- 15 years) with acute VTE and prior hospitalization for acute medical illness or surgery within 30 days (91% were at high risk with Geneva VTE risk score > or =3) were enrolled.
RESULTS: Overall, 153 (60%) patients received prophylaxis (49% pharmacological and 21% mechanical) before the onset of acute VTE. Outpatient status at the time of VTE diagnosis [odds ratio (OR) 0.31, 95% confidence interval (CI) 0.18-0.53], ongoing chemotherapy (OR 0.51, 95% CI 0.31-0.85), and recent chemotherapy (OR 0.53, 95% CI 0.32-0.88) were univariately associated with the absence of VTE prophylaxis. In multivariate analysis, intensive care unit admission within 30 days (OR 7.02, 95% CI 2.38-20.64), prior deep vein thrombosis (OR 3.48, 95% CI 2.14-5.64), surgery within 30 days (OR 2.43, 95% CI 1.19-4.99), bed rest >3 days (OR 2.02, 95% CI 1.08-3.78), and outpatient status (OR 0.38, 95% CI 0.19-0.76) remained the only independent predictors of thromboprophylaxis.
CONCLUSIONS: Although most hospitalized cancer patients were at high risk, 40% did not receive any prophylaxis before the onset of acute VTE. There is a need to improve thromboprophylaxis in cancer patients, particularly in the presence of recent or ongoing chemotherapy.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19828560     DOI: 10.1093/annonc/mdp406

Source DB:  PubMed          Journal:  Ann Oncol        ISSN: 0923-7534            Impact factor:   32.976


  12 in total

1.  Improved compliance with venous thromboembolism pharmacologic prophylaxis for patients with gynecologic malignancies hospitalized for nonsurgical indications did not reduce venous thromboembolism incidence.

Authors:  Lauren S Prescott; Lisa M Kidin; Rebecca L Downs; David J Cleveland; Ginger L Wilson; Mark F Munsell; Alma Y DeJesus; Katherine E Cain; Pedro T Ramirez; Michael H Kroll; Charles F Levenback; Kathleen M Schmeler
Journal:  Int J Gynecol Cancer       Date:  2015-01       Impact factor: 3.437

2.  Improvement of appropriate pharmacological prophylaxis in hospitalised cancer patients with a multiscreen e-alert system: a single-centre experience.

Authors:  R Figueroa; A Alfonso; J López-Picazo; I Gil-Bazo; A García-Mouriz; J Hermida; J A Páramo; R Lecumberri
Journal:  Clin Transl Oncol       Date:  2018-11-16       Impact factor: 3.405

Review 3.  Cancer-related coagulopathy (Trousseau's syndrome): review of the literature and experience of a single center of internal medicine.

Authors:  Franco Dammacco; Angelo Vacca; Pasquale Procaccio; Roberto Ria; Ilaria Marech; Vito Racanelli
Journal:  Clin Exp Med       Date:  2013-03-02       Impact factor: 3.984

Review 4.  Thromboprophylaxis guidelines in cancer with a primary focus on ambulatory patients receiving chemotherapy: a review from the Southern Network on Adverse Reactions (SONAR).

Authors:  Whitney D Maxwell; Charles L Bennett
Journal:  Semin Thromb Hemost       Date:  2012-10-30       Impact factor: 4.180

5.  Assessment of adherence to cancer-associated venous thromboembolism guideline and pharmacist's impact on anticoagulant therapy.

Authors:  Esin Aysel Kandemir; Aygin Bayraktar-Ekincioglu; Saadettin Kilickap
Journal:  Support Care Cancer       Date:  2020-08-10       Impact factor: 3.603

6.  Rationale, design and methodology of TESEO study: a registry of thrombosis and neoplasia of SEOM (Spanish Society of Medical Oncology).

Authors:  J Muñoz-Langa; P Jimenez-Fonseca; A Carmona-Bayonas; E M de Castro; P Pérez-Segura; M S Cánovas; D Gomez; L O Moran; M B G de Tejada; E Seguí; G B López; S G Adrián; M C Campos; V P Olmos; B O Portero; M S Moyano; J A S Crespo; L T Sánchez; M A Rebollo; P O Rivas; J P Altozano; Á R Lescure; A Muñoz-Martín
Journal:  Clin Transl Oncol       Date:  2020-08-13       Impact factor: 3.405

Review 7.  Venous thromboembolism in cancer patients: an underestimated major health problem.

Authors:  Jihane Khalil; Badr Bensaid; Hanan Elkacemi; Mohamed Afif; Younes Bensaid; Tayeb Kebdani; Noureddine Benjaafar
Journal:  World J Surg Oncol       Date:  2015-06-20       Impact factor: 2.754

8.  Thrombosis as a complication of central venous access in pediatric patients with malignancies: a 5-year single-center experience.

Authors:  Verena Wiegering; Sophie Schmid; Oliver Andres; Clemens Wirth; Armin Wiegering; Thomas Meyer; Beate Winkler; Paul G Schlegel; Matthias Eyrich
Journal:  BMC Hematol       Date:  2014-10-01

9.  Implementing thrombosis guidelines in cancer patients: a review.

Authors:  Dominique Farge-Bancel; Henri Bounameaux; Benjamin Brenner; Harry R Büller; Ajay Kakkar; Ingrid Pabinger; Michael Streiff; Philippe Debourdeau
Journal:  Rambam Maimonides Med J       Date:  2014-10-29

10.  Venous thromboembolism in hospitalized patients receiving chemotherapy for malignancies at Japanese community hospital: prospective observational study.

Authors:  Hiromitsu Kitayama; Tomohiro Kondo; Junko Sugiyama; Kazutomo Kurimoto; Yasuhiro Nishino; Michiaki Hirayama; Yasushi Tsuji
Journal:  BMC Cancer       Date:  2017-05-19       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.